文献速递药物不良反应与药物警戒

哪些因素促使欧盟监管机构沟通SGLT2抑制剂安全性问题?一项在线调查研究

What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study.
PubMed 文献 · Drug Saf · 2023-02-15

该研究对欧盟监管网络222名临床与药物警戒评估员进行在线横断面调查,采用联合分析评估12种安全性情景。结果显示监管者的担忧程度显著影响其更新SmPC或发送DHPC的意见,每增加10%担忧水平OR分别为13.0和13.6;担忧程度受安全性问题特征、人口学特征及态度影响。

要点

  • 监管者担忧程度每增加10%,更新SmPC的OR为13.0(95%CI 7.8-21.7)。
  • 监管者担忧程度每增加10%,发送DHPC的OR为13.6(95%CI 9.5-19.2)。
  • 安全性问题特征、人口学特征及对药物信念和风险感知均影响担忧程度。

核心结论

  • 监管者关于沟通安全性问题的意见受其担忧程度影响。
  • 监管者的担忧程度受安全性问题特征、人口学特征和态度影响。
  • 纳入多样化专家可确保风险沟通决策考虑不同观点。

研究设计与样本

  • 2021年4月至6月对欧盟监管网络临床和药物警戒评估员进行在线横断面调查。
  • 采用基于评分的联合分析,共222名监管者完成调查(64%女性;平均年龄46±10岁)。
  • 12种情景由四种特征定义:药物不良反应、信息来源、因果关系和频率。

主要发现

  • 根据情景不同,54-94%的参与者会更新SmPC,25-74%会发送DHPC。
  • 每增加10%担忧水平,更新SmPC的OR为13.0(95%CI 7.8-21.7),发送DHPC的OR为13.6(95%CI 9.5-19.2)。
  • 所有安全性问题特征均影响担忧程度。
  • 较年轻参与者、女性及东欧机构工作人员担忧程度高于较年长、男性及其他地区工作人员。
  • 对药物的信念和一般风险感知也影响担忧程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Previous studies have found differences in the communication of safety issues among medicines regulatory agencies. OBJECTIVES: To explore (1) to what extent regulators' opinions regarding the need to communicate safety issues related to sodium-glucose cotransporter-2 (SGLT2) inhibitors might be influenced by their concern about the safety issue, and (2) whether regulators' concerns might be influenced by certain characteristics of the safety issue or by the demographic and professional characteristics and attitudes of the regulators. METHODS: An online cross-sectional survey study with a rating-based conjoint analysis among clinical and pharmacovigilance assessors from the EU regulatory network was performed between April and June 2021. Regulators were invited by email, and participants were asked about their level of concern and their opinion regarding the need to communicate about 12 scenarios defined by four characteristics: adverse drug reaction, source of information, causality, and frequency. The outcomes for the first objective were to update the summary of product characteristics (SmPC; yes/no) and to send direct healthcare professional communications (DHPC; yes/no). The determinant was regulators' level of concern (range 0-100%). The outcome of the second objective was regulators' level of concern, and the determinants were the characteristics of the safety issue, demographic and professional characteristics, and attitudes of the regulators (beliefs about medicines and risk perception). RESULTS: A total of 222 regulators completed the survey (64% women; mean age 46 ± 10 years). Depending on the scenario, 54-94% and 25-74% of the participants would update the SmPC or send a DHPC, respectively. The participants' level of concern influenced their opinions regarding the need to update the SmPC and send a DHPC (odds ratio (OR) 13.0; 95% confidence interval (CI) 7.8-21.7 and OR 13.6; 95% CI 9.5-19.2, respectively, for every 10% increase in the level of concern). All characteristics of the safety issue influenced the level of concern. Younger participants, women, and those working for Eastern European agencies had a higher level of concern than older participants, men, and those working in other regions. Beliefs about medicines and general risk perception also influenced their concern. CONCLUSIONS: The opinion regarding the need to communicate safety issues was influenced by the concern of regulators. Regulators' concern was influenced by the characteristics of the safety issue, demographic characteristics, and attitudes. Diverse groups of experts regarding such factors would ensure that various views are incorporated in risk communication decisions.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Roldan Munoz S, Postmus D, de Vries ST, et al. What Factors Make EU Regulators Want to Communicate Drug Safety Issues Related to SGLT2 Inhibitors? An Online Survey Study. Drug Saf. 2023. PMID: 36790560. doi:10.1007/s40264-022-01270-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。